PierianDx, Inc.

PierianDx, Inc. specializes in clinical genomics solutions, offering an advanced platform for genomic analysis and interpretation to enhance patient care and make molecular testing globally accessible. Founded in 2014 in the US, PierianDx, Inc. provides genomic analysis services and underwent a significant operational shift with its acquisition by Summa Equity in 2022.

The original founders, Rajeev Nandan and Rakesh Nagarajan, have a history in developing innovative health tech solutions. PierianDx completed a total of 5 deals, raising USD 27. 00 mn in Series B funding, which is the total amount raised to date, involving investors like ARUP Laboratories and Health Catalyst Capital Management. Operating under the Velsera brand, PierianDx offers a comprehensive Clinical Genomics Workspace that facilitates the analysis of genomic findings and the creation of actionable reports.

The platform supports laboratories and healthcare providers in enhancing the quality of genomic testing and optimizing workflows, particularly in regions such as Central Europe where they have formed partnerships for NGS data diagnostics. PierianDx generates revenue primarily through subscription-based models for its Clinical Genomics Workspace and associated professional services, which include assay selection and clinical interpretation support. This transactional model fosters long-term partnerships, enabling clients to access PierianDx's genomic knowledgebase while benefitting from continuous updates to their services. Following the acquisition by Summa Equity in 2022, PierianDx is focused on expanding its offerings and geographic reach.

The company plans to launch new products designed to enhance genomic testing capabilities within the next year. Targeted expansion into new markets includes increasing presence in Asia and South America by 2024. Recent funding will support these initiatives, allowing for broader deployment of their genomic solutions in healthcare institutions.